Jasper Therapeutics effects 1-for-10 reverse stock split to regain Nasdaq compliance

Jasper Therapeutics, Inc.

Reverse split effective 12:01 a.m. ET on Jan 4, 2024; shares begin trading split-adjusted same day.
Common stock CUSIP changed to 471871202; trading symbol remains JSPR.
Warrants (JSPRW) adjusted: 10 pre-split warrants exercisable for 1 share at $115.00 exercise price.
No fractional shares issued; cash in lieu paid based on Jan 3, 2024 closing price.
Split approved by board on Dec 22, 2023, after stockholder authorization on Dec 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Jasper Therapeutics, Inc.: Effected a 1-for-10 reverse stock split to regain compliance with Nasdaq minimum bid price requirement (effective 2024-01-04).

Change: charter amendment
Effective: 2024-01-04

Exact text from the filing

The Reverse Stock Split was effective at 12:01 a.m., Eastern Time, on January 4, 2024, and the Common Stock is expected to begin trading on a Reverse Stock Split-adjusted basis on the Nasdaq Capital Market at the opening of the market on January 4, 2024.

View on SEC.gov

Browse all governance changes →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-000980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.